Pfizer (NYSE:PFE), which develops and sells biopharmaceutical products worldwide, closed today's session (Dec. 16) at $25.53, down 3.41%. Trading volume reached 108.1 million shares, almost 60% above its three-month average.
Tuesday’s move followed Pfizer's announcement trimming 2025–2026 revenue expectations and highlighting faster COVID-19 erosion. Investors will watch to see whether new products and deals can restore earnings growth.
The S&P 500 (SNPINDEX:^GSPC) slipped 0.26% to 6,799, while the Nasdaq Composite (NASDAQINDEX:^IXIC) added 0.23% to finish at 23,111. Pfizer’s commentary impacted its industry peers as well. Merck (NYSE:MRK) and Johnson & Johnson (NYSE:JNJ) fell 1.99% and 2.27%, respectively, as investors reassessed large pharma earnings power.
Pfizer cut its 2025 revenue guidance from to $62 billion, down from between $61 billion and $64 billion. It reaffirmed its 2025 adjusted EPS of $3.00 - $3.15.
It told investors it is expecting flat growth for 2026, with anticipated revenues between $59.5 billion and $62.5 billion. This is down to falling revenue from COVID drugs and expiring patents.
The company said it is cutting costs and investing the proceeds into R&D. For example, it recently acquired a biopharmaceutical company focused on obesity and cardiometabolic diseases. It will push ahead with obesity drug trials in 2026. However, it could take time for newer initiatives to bear fruit.
When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 962%* — a market-crushing outperformance compared to 193% for the S&P 500.
They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.
See the stocks »
*Stock Advisor returns as of December 16, 2025.